The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.

"Declarations Ethics approval and consent to participate: This study was approved by the IRB (20192825) and performed in compliance with the Declaration of Helsinki and is consistent with International Council for Harmonisation/Good Clinical Practice and applicable regulatory requirements. Written informed consent was required for eligibility to participate in this study.Consent for publication: Not applicable.Author contributions:Virgilio G. H. Evidente: Investigation; Writing – review & editing.Daryl Dekarske: Methodology; Validation; Writing – review & editing.Bruce Coate: Data curation; Formal analysis; Methodology; Writing – review & editing.Victor Abler: Conceptualization; Funding acquisition; Methodology; Project administration; Writing – review & editing.Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Acadia Pharmaceuticals Inc.Competing interests: VGHE has received personal compensation for serving as a consultant or speaker for Adamas, Amneal, Kyowa Kirin, Ipsen, Lundbeck, Medtronic, Merz, Neurocrine, Revance, Sunovion, Teva, and UCB; and has received research support from AbbVie, Acadia, Aeon, Aptinyx, CND Life Sciences, Ipsen, IRLAB, Jazz Pharmaceuticals, Lundbeck, Neuraly, Neurocrine, Pharma Two B, Revance, Scion Neurostim, and Sunovion. DD, BC, and VA are employees of Acadia Pharmaceuticals Inc.Availability of data and materials: Clinical study documents are confidential and the property of Acadia. The protocol or statistical analysis plan is available upon request. Competing interests: VGHE has received personal compensation for serving as a consultant or speaker for Adamas, Amneal, Kyowa Kirin, Ipsen, Lundbeck, Medtronic, Merz, Neurocrine, Revance, Sunovion, Teva, and UCB; and has received research support from AbbVie, Acadia, Aeon, Aptinyx, CND Life Sciences, Ipsen, IRLAB, Jazz Pharmaceuticals, Lundbeck, Neuraly, Neurocrine, Pharma Two B, Revance, Scion Neurostim, and Sunovion. DD, BC, and VA are employees of Acadia Pharmaceuticals Inc."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Acadia Pharmaceuticals Inc."

"Trial registration: ClinicalTrials.gov Identifier: NCT04292223."